Wellington Management Group
ANTX icon

Wellington Management Group’s AN2 Therapeutics ANTX Stock Holding History

Wellington Management Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,600
Closed -$250K – 2069
2022
Q1 		$250K Buy
+16,600
New +$252K ﹤0.01% 2047

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wellington Management Group's ANTX Position: Q2 2022 in Review

Wellington Management Group sold out of AN2 Therapeutics (ANTX) in Q2 2022, closing a stake of 16,600 shares — an estimated $250K sold.

Wellington Management Group first reported a position in ANTX in Q1 2022 and held it in 1 quarter. The position peaked at $250K in Q1 2022. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2022.

  • Wellington Management Group reported no remaining AN2 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Wellington Management Group sold 16,600 AN2 Therapeutics shares in Q2 2022, an estimated $250K.
  • Wellington Management Group first reported a position in AN2 Therapeutics in Q1 2022 and held it in 1 quarter.
  • Wellington Management Group's AN2 Therapeutics position peaked at $250K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2022.

Based on Wellington Management Group's 13F filing for Q2 2022, filed 15 Aug 2022.